Ingevity reported strong Q2 2026 results with adjusted EBITDA up 14%, raising full-year guidance driven by its carbon business in hybrid vehicles. It is simplifying its portfolio by selling Advanced P
Ingevity reported improved Q2 2026 profitability despite lower sales and completed a multi-year share repurchase program. Analysts suggest the stock may be undervalued at current levels, though its hi
Ingevity Corp CFO Phillip John Platt had 3,294 shares withheld for tax obligations on July 24, 2026, retaining 28,339 direct holdings post-transaction.
As of December 31, 2025, Brown Advisory Small-Cap Fundamental Value Fund held 508,852 shares of Ingevity Corp valued at $30.11 million. The fund reported an estimated gain of $712,304.81 through 19 tr
Ingevity Corp Senior Vice President Ryan C. Fisher had 168 shares withheld at $73.86 per share to cover tax obligations from vested RSUs, retaining 18,431 direct holdings.
Wellington Management Group filed an amended Schedule 13G/A disclosing 1.49 million shares (4.24%) of specialty chemical firm Ingevity Corp as of March 31, 2026.
Ingevity Corp forecasts 2025 revenue between $1.05B and $1.15B, missing consensus estimates. The specialty chemicals firm faces investor caution due to lower guidance and moderate financial health sco
Vanguard Capital Management filed a Schedule 13G disclosing a 5.26% stake in Ingevity Corp (NGVT) as of March 31, 2026. The filing indicates Vanguard holds sole dispositive power over 1.85 million sha
Vanguard Portfolio Management disclosed a 6.27% ownership stake in Ingevity Corp through a Schedule 13G filing, representing 2,209,879 shares.
Ingevity Corp (NGVT) reported a 126% one-year shareholder return despite a rich P/S ratio compared to industry peers. The company plans to improve margins by divesting non-core assets and focusing on
Simcoe Capital Management holds 1.02 million shares of Ingevity Corp valued at $60.42 million, representing 10.81% of its portfolio, along with recent earnings and analyst ratings.
ChemBrief